ARCHIVES

Wall Street Analyst Who Sounded Alarm Over Prostate Cancer Drug Provenge In JNCI Settles With SEC Over Shorting Dendreon Stock

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

Rauscher To Leave ACS when It Moves To Atlanta; Gadberry To Retire In March; Other VPs Stay On

January 8, 1988

Zofran Label Change Includes Warnings of QT Prolongation

September 30, 2011

Massive New Radiation Research program Costing From $300-$400 Million Over 10 Years Suggested

February 11, 1977

HHS Says NIH Improperly Used Program For Scientists To Hire Administrators.

July 13, 2001

ACCP Publishes Guidelines Recommending Low-Dose CT

May 31, 2013

Greatest Need Of Cancer Care Givers: “Will to Work Together,” ACCC President Anderson Says

August 15, 1986